BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting
- Total group revenues plus 35%, organic plus 19%
- Both segments contribute with double digit organic growth
- Cash on-hand improved
BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, had a strong start into the fiscal year with very satisfying revenue growth in both divisions. Cash on hand improved by € 2.4 million to € 10.8 million from last quarter which includes the disposal proceeds from L.A. Schmitt GmbH. Adriaan Moelker, CEO BRAIN Biotech AG, states: “BRAIN continues well on its path of profitable growth. Over the last three years we have prepared the ground by structural changes to our company portfolio, technology additions, cultural change and people management. As a result we have now built a solid base for growth also in the coming years.”
The revenue of the BRAIN Group grew to € 13.7 million in Q1 2022/23 fiscal year. Compared with the previous year (€ 10.2 million), this represents an increase of 34.5%. On an organic basis – in other words, excluding the acquisition of Breatec-Group and the divestment of L.A. Schmitt GmbH – revenue also increased by a strong 19.4%. This revenue increase in organic terms has been driven by both segments. At € 13.5 million, the total operating performance was up by € 3.1 million. BRAIN Biotech’s adjusted EBITDA was slightly down in the first quarter from € -0.3 million to € -0.4 million reflecting higher expenditures for personnel and higher project investments.
Important events for the quarter
BRAIN Biotech AG was informed on November 17 by its anchor investor MP Beteiligungs-GmbH, Kaiserslautern, that MP Beteiligungs-GmbH now holds approximately 45% of the total share capital in BRAIN Biotech AG. The shareholding of MP Beteiligungs-GmbH in BRAIN Biotech AG has been continuously expanded over the course of 2022 through share acquisitions in the open market. With the completion of an additional major block transaction, the total shareholding has grown to approximately 45%. MP Beteiligungs-GmbH intends to continue to accompany the development of BRAIN Biotech AG on the capital market in the long-term and considered the weak capital market environment for the BRAIN Biotech AG share price as a good investment opportunity.
BRAIN Biotech and rare sugars expert Bonumose announced that they have reached initial project milestones as part of their strategic collaboration. The companies aim to improve the performance of several enzymes that catalyze cascade reactions in the continuous production of low-calorie, ultra-low-glycemic, naturally occurring sweeteners. Bonumose has developed a patented process for producing tagatose and allulose, which eliminates several processing steps and significantly increases yields during the production process. The company uses multiple enzymes within the synthesis cascades and BRAIN Biotech is optimizing several of these enzymes using enzyme engineering.
Development of segments
The BioIndustrial segment consists mainly of the group’s industrial scale product business. Revenue in the BioIndustrial segment grew strongly by 43.5% from € 7.4 million to € 10.6 million. On an organic basis excluding the acquisition of Breatec Group revenues increased by 23%. Without selected supply chain constraints the organic growth could have been even more dynamic. Adjusted EBITDA for the segment grew by 18.8% or € 0.2 million to € 1.1 million mainly driven by the higher level of turnover.
The BioScience segment includes the research business with industrial partners and the company’s own incubator pipeline. Revenue in the BioScience segment was up by a solid all organic 10.5%, from € 2.8 million to € 3.1 million. This sales increase is mainly attributable to larger project volumes with existing customers and selected price increases for our contract research services. The adjusted EBITDA of the segment is reported at € -1.4 million and includes strong investments into the genome-editing activities branded under Akribion Genomics.
Michael Schneiders, CFO at BRAIN Biotech AG, looks optimistically into the future: “The start into our new financial year 2022/23 has been the continuation of the strong operating performance of last year. We are very pleased with the double digit growth rate in both operating segments. Solid growth also builds the basis to handle the ongoing challenges of an inflationary labor and material cost base. We look optimistic into the next three quarters of our business year.”
Key financials (first three months of the financial year 2022/23)
| (in € million) | 3M 2022/23 | 3M 2021/22 |
|---|---|---|
| Revenues | 13.7 | 10.2 |
| BioScience | 3.1 | 2.8 |
| BioIndustrial | 10.6 | 7.4 |
| Total operating performance1 | 13.5 | 10.4 |
| Adjusted EBITDA2 | -0.4 | -0.3 |
| EBITDA | -0.7 | -0.6 |
| Operating cash flow | -2.0 | -0.2 |
| 31.12.2022 | 31.12.2021 | |
| Cash and cash equivalents | 10.8 | 22.7 |
1 Revenues + change in inventories + other income including R&D grants
2 The reconciliation from adjusted to unadjusted EBITDA can be found in the 3M report for the period ended December 31st, 2022
Further information:
BRAIN Biotech AG 3M Report 2022/23:
https://www.brain-biotech.com/investors/financial-publications
Financial Calendar:
https://www.brain-biotech.com/investors/financial-calendar
About BRAIN
BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.
BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).
Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.
BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.
For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.